QNTM

Quantum Biopharma Subordinate Voting SharesD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-20

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$5.75

+89.1% vs current

Most likely

Base case

45%

Probability

Target price

$4.35

+43.1% vs current

B-

Bear case

30%

Probability

Target price

$2.60

-14.5% vs current

AI sentiment snapshot

Latest data as of 2026-06-11

AI commentary

Recent headline flow is directionally positive around Lucid-MS and liquidity, but the evidence base is still thin and mostly company-driven. The stored May 7 release provides the main primary-source support for the IND submission, Phase 2 setup, liquidity runway, and Unbuzzd financing/commercialization optionality. There is still no usable analyst-revision set, no SEC filing excerpt in the packet, and no meaningful social-context signal, so this remains a cautious monitoring view rather than a high-conviction rerating call.

RankAlpha Sentiment Codex - 2026-06-11

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-31eventQ1 liquidity update reduced near-term financing pressureHigh impact

The stored Q1 release said combined cash, cash equivalents, and digital assets were US$9.8 million at March 31, 2026, operating cash use fell 60% year over year, and management said planned operations were funded to about July 2027. That lowers immediate dilution pressure, though part of liquidity depends on digital-asset value and the company remains pre-commercial. [#PR-EARNINGS-2026-05-07]

2026-09-30catalystLucid-MS moves from IND filing toward Phase 2 setupHigh impact

The May 7 release says Quantum formally submitted an IND for Lucid-MS, appointed a principal investigator, and entered a binding LOI with Allucent to conduct the planned Phase 2 MS trial. For a microcap biotech, confirmation that the program keeps advancing is the clearest value driver, but FDA feedback, protocol timing, and execution remain uncertain. [#PR-EARNINGS-2026-05-07]

2026-12-31catalystUnbuzzd IPO financing and commercialization setup remains a secondary optionMedium impact

The May 7 release said Unbuzzd completed a corporate reorganization and hired a CEO to launch IPO financing and lead nationwide commercialization. This provides another future-looking hook, but it is less directly tied to the core biotech valuation case than Lucid-MS and should be treated as execution-dependent optionality. [#PR-EARNINGS-2026-05-07]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-11 • Updated nightlySource: Internal modelMethodology